explore -WSS

explore

author：leisure time 2025-09-30 00:51:25 - browse：58618

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Why health records don't always know when patients are dead

Virtual care provider acquires bankrupt Pear's prescription apps

Virtual care provider acquires bankrupt Pear's prescription apps

CRISPR gene editing developments we’re watching in 2024

Violet CEO on training clinicians to promote more inclusive care

NIH study of ME/CFS points to clear biological hallmarks

hotspot

explore

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

R1 RCM gets $5.8 billion buyout offer from private equity firm

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Community Health Systems hospitals under DOJ investigation

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage beneficiaries sue Humana over algorithm use

At least 13 dead in Texas as scorching temps continue

David Ricks of Eli Lilly: best biopharma CEO of 2023

As demand for Covid shots wanes, Moderna seeks its next success

Bristol Myers buys into radiopharmaceuticals with RayzeBio

knowledge

Violet CEO on training clinicians to promote more inclusive care

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Three trends to watch in biotech in 2024

hotspot

focus

explore

focus